Background: Lynch syndrome (LS) accounts for 5% of all endometrial cancer (EC)
In patients with LS, colorectal and endometrial cancers are the most common "sentinel cancers" with which patients present to clinical attention. 7, 11, [16] [17] [18] [19] The most common and clinically relevant mutations in LS occur in the MLH1, MSH2, MSH6, PMS2, and EPCAM genes. 20, 21 A report from the prospective LS database followed over 3000 patients for a total of 24 475 person years and determined the cumulative incidences of EC (at age 75) to be 43%, 57%, and 46%, for patients with mutations in MLH1, MSH2, and MSH6, respectively. patients had no family history of LS-associated malignancy. 33 These findings emphasize the considerable number of patients whose diagnosis of LS would be missed by the existing criteria.
Germline mutation sequencing is the gold standard test for confirming the diagnosis of LS but is currently too expensive to be used as a screening tool. The sensitivity and specificity of MSI testing vary depending on the specific mutated gene: While testing is 80% to 91% sensitive and 90% specific for MLH1 or MSH2 mutations, it is 55% to 77% sensitive and 90% specific for MSH6 or PMS2 mutations. 3 By contrast, immunohistochemistry (IHC) testing is 83% sensitive and 89% specific, regardless of which MMR gene is involved. 3 In addition to its applicability to all mutated genes, IHC is also faster to perform, less expensive, and easier to test on biopsy samples than MSI. 36 The aforementioned study by Goodfellow et al tested a combination of techniques, including MMR protein IHC, MLH1 methylation analysis, and MSI testing. 35 The study identified a patient who initially tested negative for LS using the IHC method, but positive via MSI, highlighting the differences in sensitivity among assays. A separate • Patients with a first-or second-degree relative with a known mutation in a mismatch repair gene.
• Families with few female relatives, as this may lead to an underrepresentation of female cancers despite the presence of a predisposing family mutation.
• Hysterectomy and/or oophorectomy at a young age in multiple family members, as this might mask a hereditary gynecologic cancer predisposition.
• Presence of adoption in the lineage. 60 Germline mutations in MSH2, MSH6, PMS2, or MHL1 (and absent MHL1 methylation) were associated with younger age of onset, superficial tumor invasion, and early-stage disease, whereas sporadic endometrial cancer was the opposite. Although these mutations also predisposed patients to having other LS-associated malignancies, they were also more sensitive to adjuvant immune therapy than sporadic EC (with nonmutated MMR genes), resulting in an overall more favorable prognosis.
| CANCER SURVEILLANCE IN PATIENTS WITH LYNCH SYNDROME
A multicenter study by Møller et al assessed cancer detection among LS patients undergoing prospective routine colonoscopic and gynecologic surveillance. 61 The N = 19, 6% ). When the data were stratified according to specific gene mutations, alterations in MLH1, MSH2, MSH6, and PMS2 resulted in a cumulative prevalence at age 70 of 34%, 51%, 49%, and 24%, respectively, for endometrial cancer, and 11%, 15%, 0%, 0%, respectively, for ovarian cancer. The overall 10-year survival rate following the development of any cancer was 87%. However, if the sentinel cancer was colorectal, the 10-year survival rate was extremely low (9%), while it was significantly higher for those who first developed endometrial cancer (98%) or ovarian cancer (89%).
56
To monitor EC in patients with LS, we recommend the use of endometrial biopsy (with or without hysteroscopy), beginning at the age of 30 to 35 years, or 3 to 5 years prior to the age of onset of their youngest affected family member in premenopausal women, and traditional ultra- 
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